share_log

Fewer Investors Than Expected Jumping On Intco Medical Technology Co., Ltd. (SZSE:300677)

予想よりも少ない投資家がintco medical technology株式会社(SZSE:300677)に参加しています

Simply Wall St ·  11/10 08:56

When close to half the companies in China have price-to-earnings ratios (or "P/E's") above 37x, you may consider Intco Medical Technology Co., Ltd. (SZSE:300677) as an attractive investment with its 24.3x P/E ratio. However, the P/E might be low for a reason and it requires further investigation to determine if it's justified.

Intco Medical Technology certainly has been doing a good job lately as its earnings growth has been positive while most other companies have been seeing their earnings go backwards. One possibility is that the P/E is low because investors think the company's earnings are going to fall away like everyone else's soon. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

big
SZSE:300677 Price to Earnings Ratio vs Industry November 10th 2024
Keen to find out how analysts think Intco Medical Technology's future stacks up against the industry? In that case, our free report is a great place to start.

Is There Any Growth For Intco Medical Technology?

In order to justify its P/E ratio, Intco Medical Technology would need to produce sluggish growth that's trailing the market.

Taking a look back first, we see that the company grew earnings per share by an impressive 134% last year. Despite this strong recent growth, it's still struggling to catch up as its three-year EPS frustratingly shrank by 92% overall. Therefore, it's fair to say the earnings growth recently has been undesirable for the company.

Looking ahead now, EPS is anticipated to climb by 98% during the coming year according to the one analyst following the company. With the market only predicted to deliver 41%, the company is positioned for a stronger earnings result.

With this information, we find it odd that Intco Medical Technology is trading at a P/E lower than the market. It looks like most investors are not convinced at all that the company can achieve future growth expectations.

The Key Takeaway

Generally, our preference is to limit the use of the price-to-earnings ratio to establishing what the market thinks about the overall health of a company.

Our examination of Intco Medical Technology's analyst forecasts revealed that its superior earnings outlook isn't contributing to its P/E anywhere near as much as we would have predicted. When we see a strong earnings outlook with faster-than-market growth, we assume potential risks are what might be placing significant pressure on the P/E ratio. At least price risks look to be very low, but investors seem to think future earnings could see a lot of volatility.

Having said that, be aware Intco Medical Technology is showing 2 warning signs in our investment analysis, you should know about.

You might be able to find a better investment than Intco Medical Technology. If you want a selection of possible candidates, check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする